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MT-ND5 mutation exhibits highly variable neurological manifestations at low mutant 
load 
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Abstract (196 words) 
Mutations in the m.13094T>C MT-ND5 gene have been previously described in three cases 
of Leigh Syndrome (LS). In this retrospective, international cohort study we identified 20 
clinically affected individuals (13 families) and four asymptomatic carriers.. Ten patients 
were deceased at the time of analysis (median age of death was 10 years (range: 5·4 months -
37 years, IQR= 17·9 years). Nine patients manifested with LS, one with mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), and one with Leber 
hereditary optic neuropathy. The remaining nine patients presented with either overlapping 
syndromes or isolated neurological symptoms. Mitochondrial respiratory chain activity 
analysis was normal in five out of ten muscle biopsies. We confirmed maternal inheritance in 
six families, and demonstrated marked variability in tissue segregation, and phenotypic 
expression at relatively low blood mutant loads. Neuropathological studies of two patients 
manifesting with LS/MELAS showed prominent capillary proliferation, microvacuolation 
and severe neuronal cell loss in the brainstem and cerebellum, with conspicuous absence of 
basal ganglia involvement. These findings suggest that whole mtDNA genome sequencing 
should be considered in patients with suspected mitochondrial disease presenting with 
complex neurological manifestations, which would identify over 300 known pathogenic 
variants including the m.13094T>C. 
 
Keywords:  Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes 
(MELAS); Leigh syndrome (LS); mitochondrial DNA; heteroplasmy; neuropathology    
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INTRODUCTION  
Defects in oxidative phosphorylation (OXPHOS) are an important cause of human morbidity 
and mortality, with complex I (NADH-ubiquinone oxidoreductase) deficiency recognized as 
the most commonly observed OXPHOS defect.1 Complex I (NADH: ubiquinone 
oxidoreductase) is the largest component of the oxidative phosphorylation system (OXPHOS) 
composed of 45 subunits that, in supercomplex formation with respiratory chain complexes 
III and IV, drives the generation of a transmembrane protein gradient powering adenosine 
triphosphate (ATP) synthesis.  Complex I requires 14 evolutionary conserved core subunits 
for its catalytic function: seven mtDNA-encoded NADH-dehydrogenase (ND) core subunits 
(ND1-6, ND4L) and seven nuclear DNA (nDNA) encoded subunits (NDUFV1, NDUFV2, 
NDUFS1, NDUFS2, NDUFS3, NDUFS7 and NDUFS8), in addition to 31 supernumerary 
subunits, whose exact roles are yet to be fully defined.2 The MT-ND5 gene of complex I, 
appears to be a mutational ‘hot spot’ 3 and linked to a variety of clinical phenotypes ranging 
from single organ involvement, such as isolated exercise intolerance4 or Leber hereditary 
optic neuropathy (LHON),5 to multisystem disease manifesting as renal failure and 
myopathy,6 Leigh syndrome (LS),7,8 mitochondrial encephalomyopathy, lactic acidosis and 
stroke-like episodes (MELAS),9,10 or as a combination of overlapping syndromes including 
LS/MELAS,7,11 MELAS/myoclonic epilepsy and ragged red fibres (MERRF),12 
LHON/MELAS13  and LS/MELAS/LHON.10 The limited understanding of the natural history 
of disease caused by such mutations presents significant challenges in clinical practice, 
particularly in relation to pre-symptomatic genetic testing of at-risk family relatives.   
The m.13094T>C mutation, in the MT-ND5 gene, is considered a rare pathogenic 
variant that has been previously reported in association with LS but the full phenotypic 
spectrum has remained poorly understood.14,15 We present the clinical, radiological, and 
histopathological data of 24 subjects who harbor the m.13094T>C mutation. We have also 
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studied the neuropathological changes in two patients with LS/MELAS overlap syndrome, to 
fully elucidate the spectrum of m.13094T>C-related mitochondrial disease and to offer 
guidance on management and genetic counseling.  
 
MATERIALS AND METHODS 
Study design and patients 
This retrospective, international cohort study was done at the NHS Highly Specialised 
Service-funded Mitochondrial Diagnostic Centers in Newcastle upon Tyne and London, UK. 
These included patients referred from four other countries: China, South Africa, Greece and 
Japan. Eligible participants were genetically confirmed to harbor the m.13094T>C mutation 
(p.Val253Ala) in MT-ND5 over a 17 year period (January 2000 – October 2017); their 
maternal family members were traced and examined whenever possible.  
This study was approved and performed under the ethical guidelines issued by our institution 
for clinical studies, and complied with the declaration of Helsinki. 
Clinical Presentation and Phenotypic Evaluation 
Each patient was assessed by a specialist (pediatrician, adult neurologist and/or 
ophthalmologist) at each center, and their medical records were comprehensively reviewed. 
The clinical presentation of individual patients and their family pedigree are provided in 
Supplemental data and Supplemental Figure 1. Where possible, common clinical 
syndromes described in mitochondrial disease were assigned (and agreed by all authors).  
Histopathological and Biochemical Studies 
Standard histological (hematoxylin and eosin (H&E) and modified Gomori Trichome stains), 
histochemical (cytochrome c oxidase (COX), succinate dehydrogenase (SDH), and sequential 
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COX–SDH and biochemical assessments of muscle tissue were performed as described 
elsewhere (Supplemental Table 1). Fresh tissue was fixed in 2.5% glutaraldehyde buffered 
to pH 7.4 with phosphate buffer and post-fixed in OsO4 and embedded in Epon LX-112. 
Ultra-thin sections were examined in an electron microscope (JEOL⁃1500, Japan) for Patient 
5. 
Molecular Genetics 
Extraction of total DNA was performed as per standard procedure. The whole mitochondrial 
genome was sequenced, and pyrosequencing assay was used16 to screen for and quantify the 
m.13094T>C mutation (GenBank Accession number: NC_012920.1) for 13 patients (Patients 
1, 1.1, 1.2, 2, 2.1, 2.2, 2.4, 3, 3.1, 4, 6, 8 and 8.1). The assay could reliably detect a level of 
>3% of mutant mtDNA. Restriction fragment length polymorphism (RFLP) analysis was 
performed to quantify the m.13094T>C heteroplasmy level in Patients 5, 12 and 13, with the 
sensitivity of ~5%.14 The mutant heteroplasmy level was quantified using next-generation 
sequencing (NGS) for Patients 7, 7.1, 7.2, 9 and 10 (sensitivity >10%).  
 
Neuropathological Studies 
Neuropathological investigations were performed on postmortem brain tissues from two 
patients (patients 1.2 and 8). Cresyl fast violet (CFV), H&E and Luxol fast blue with H&E 
counterstain were used on formalin-fixed paraffin-embedded tissues to determine neuronal 
population density and degree of myelination. Immunohistochemistry to determine the 
expression levels of mitochondrial respiratory chain subunits, including complex I subunit 
NADH: ubiquinone oxidoreductase subunit B8 (NDUFB8) and complex II subunit succinate 
dehydrogenase subunit A (SDHA), were performed on 5 micron thick sections as previously 
described.17 
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Statistical Analysis 
Non-parametric, continuous data were presented as median (range and inter-quartile range 
(IQR)). Correlation of mtDNA heteroplasmy level of different tissues and age of disease 
onset was examined using Spearman rank correlation test. Statistical significance was 
determined at p < 0.05. Data were managed and analyzed with IBM SPSS for Windows 
version 22. 
 
RESULTS 
Patient Cohorts 
Clinical features of 24 individuals from 13 families are summarised in Table 1. The median 
age of disease onset was 5.5 years (n=20, range: 6 weeks to 34 years, IQR= 13years; the age 
of onset not known for two patients). Four individuals were clinically unaffected; they were 
ascertained pre-symptomatically due to diagnosis in other family members. Ten patients 
(42%) were deceased, and the median age of death was 10 years (range: 5.4 months to 37 
years, IQR= 17.9 years).  
Eleven patients presented with distinctive clinical syndromes previously described in 
mitochondrial disease. However, the remaining patients (n=9) manifested with an isolated 
neurological symptom or overlapping syndromes, of which central nervous system was most 
commonly affected (Table 1). Centrally mediated respiratory failure or apnoea was 
documented in nine patients (38%) with LS, including an adult patient who presented at the 
age of 22 years (Patient 10). Refractory focal onset seizures with or without evolution to 
bilateral convulsions occurred in eight patients (35%).  
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Radiological Imaging 
Cranial magnetic resonance imaging (MRI) was available for analysis in 17 patients (Table 
2, Figure 1 and Supplemental Figure 2). The most common T2/ FLuid Attenuation 
Inversion Recovery (FLAIR)-signal abnormalities were present in the midbrain (n=12) and 
thalamus (n=9: bilateral, symmetrical changes; n=3: unilateral) followed by pons (n=10) and 
medulla (n=9). Brainstem changes in two patients (Patients 6 and 8), initially was initially 
misdiagnosed as a low-grade glioma, although gadolinium-enhancement was absent. 
Subacute cortical and subcortical signal changes were identified in six patients that were 
consistent with stroke-like lesions. Two patients had multiple cortical lesions including 
lesions within the cerebellar hemispheres (Patients 1.2 and 5), suggestive of cross cerebellar 
diaschisis. Cervical cord lesions were also identified in six patients. 
Signal abnormalities within the basal ganglia, classically seen in LS, were only 
identified in two patients (Patients 11 and 13). 
Histopathological and Biochemical Analyses 
Histopathological and histochemical evaluation was normal in most patients except minor 
changes detected in the skeletal muscle of three patients: minor ragged red fibers (n=1), lipid 
droplets and abnormal mitochondrial ultrastructure (n=1) and occasional angular atrophic 
fibers (n=1). Mitochondrial respiratory chain activity was measured in skeletal muscle tissue 
from 10 patients. One patient demonstrated isolated complex I deficiency, one patient with 
combined complex I and III deficiencies, two patients with combined complex I and IV 
deficiencies and one patient had low complex I and II activity in postmortem tissue, which 
was caused by significant delay in tissue handling. The remaining six cases demonstrated 
normal respiratory chain activity (Supplemental Table 1).  
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Molecular Genetics 
Thirteen probands were identified to harbor the m.13094T>C mutation through whole 
mtDNA sequencing after screening negative for common mtDNA point mutations including 
m.3243A>G, m.8344A>G, MTATP6, and MTATP8 genes. The mutation was identified in 
nine individuals by direct sequencing of the mtDNA point mutation through pedigree and 
segregation analysis. Maternal inheritance of the m.13094T>C mutation was confirmed in six 
family pedigrees. The m.13094T>C mutation was not detected in the blood of Patient 1 
(measured at age 37 years) with a severe, adult-onset MELAS phenotype although was 
detected at 51% in urine. Patient 2.2 was presumed an obligate carrier even though the 
m.13094T>C mutation was not detectable in blood (measured at age 74 years). There was no 
tissue sample available for testing in Patient 2.3. The asymptomatic mother of patient 3 was 
demonstrated to harbor the m.13094T>C mutation at mtDNA heteroplasmy levels of 19%, 
27% and 45% in blood, muscle, and urine respectively (measured at age 24 years). The 
quantification of mutant mtDNA heteroplasmy level was not performed in two patients due to 
no access to tissue samples (Patient 2.3) and only Sanger sequencing was performed in 
Patient 11 (the mutant load in muscle appeared higher than blood; sensitivity >25%).    
There was a statistically significant negative correlation between blood mtDNA 
heteroplasmy level and age (Spearman rho= -0.883, p<0.001; Figure 2A). Among the 
patients with mutant mtDNA load quantified in more than one tissue (n=12), the mutant 
heteroplasmy levels in muscle (65% +/- 20%; n=10) and/or urine (40% +/- 27%; n=8) were 
consistently higher than blood (24% +/- 22%; n=16) (Figure 2B). The discrepancy between 
muscle and blood mtDNA heteroplasmy ranged from 3 to 75% in seven patients; the 
discrepancy between urine and blood mtDNA heteroplasmy levels ranged from 5 to 51% in 
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seven patients. Whole exome sequencing (methods described elsewhere18) was performed to 
investigate the cause of optic neuropathy in Patient 7. This excluded other known causative 
genes (including OPA1). 
The m.13094T>C mutation load of a number of post-mortem tissues was analyzed 
from Patients 1.2 and 13 exemplifying the varied tissue segregation that is characteristic of 
this mtDNA mutation (Table 3). The m.13094T>C mutation load was specifically 
determined in brain homogenate samples from patients 1.2 and 8 demonstrating lower mutant 
load within neuronal tissues (median= 61%, range: 47-69%) compared to other tissues 
despite both manifesting with extensive neurological sequelae (Table 3).  
Muscle (Spearman rho=0.192, p= 0·62) and urine (Spearman rho= -0.80, p= 0.20) 
mutant mtDNA heteroplasmy levels did not correlate with the age of disease onset. There 
was no significant difference in mean mutant heteroplasmy level in different syndromic 
categories (p=0.122).     
 
Neuropathological Findings 
The major neuropathological findings for patients 1.2 and 8 are summarised in Supplemental 
Table 2).  In patient 1.2, posterior cerebellar cortex demonstrated multiple areas of necrotic 
lesions ranging from atrophy of the molecular layer, Purkinje cell dropout and granule cell 
loss (Figure 3A), to total necrosis of the cerebellar cortex that also affected the underlying 
white matter (Figure 3B). Concerning topographical distribution, lesions were most severe in 
the brainstem nuclei (Figure 3C and D), the thalamic and subthalamic nuclei (Figure 3E 
and F) and primary visual cortex (Brodmann area 17) (Figure 3G). At a microscopic level, 
changes such as prominent capillary proliferation, microvacuolation and severe neuronal loss 
were frequently observed in fixed cerebral and cerebellar hemispheres, and right brainstem 
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compatible with LS.  Downregulation of complex I subunit (NDUFB8) was evident in the in 
the pons and cerebellar cortex of patient 1.2, and lesioned thalamus and occipital cortex of 
patient 8 (Supplemental Figure 3). 
DISCUSSION 
In this study, we have identified marked clinical heterogeneity with a continuous spectrum of 
overlapping symptoms associated with the m.13094T>C mutation. However within that 
clinical heterogeneity, at certain points in the course of disease, several distinct clinical 
syndromes associated with mutations in the MT-ND5 gene were clearly discernible: early 
onset LS (38%), late childhood/early adulthood-onset LS/MELAS overlap syndrome (13%) 
and LHON (4%) (not previously recognized in association with the m.13094T>C mutation). 
LS frequently manifested with a typical illness trajectory including hypotonia, cranial nerve 
palsies, cerebellar ataxia, and developmental regression; with relapses in clinical status often 
triggered by inter-current illness. Brainstem dysfunction (manifesting as centrally-mediated 
respiratory failure and lability in blood pressure), commonly occurred as a pre-terminal event. 
Patients with the LS/MELAS overlap syndrome typically presented with refractory focal 
seizures and stroke-like lesions (as classically seen in MELAS). Additional features of 
brainstem dysfunction, including acute-onset ptosis, a complex eye movement disorder and 
worsening ataxia (as classically seen in LS) were not infrequent. Neuropsychiatric symptoms 
such as excessive anxiety, low mood, and hypersomnolence, in addition to cognitive 
impairment were features accompanying stroke-like episodes. A progressive gait disorder 
with truncal ataxia was a prominent clinical feature in three adult patients (13%), and 
additional neurological features such as strabismus (Patient 2.4), axonal neuropathy and 
stroke-like episode (Patient 2) were identified. Interestingly, optic neuropathy was the first 
clinical manifestation in four patients (Patients 1, 2.4, 7 and 7.1); however, additional severe 
central nervous system (CNS) involvement evolved in two patients (Patients 1 and 2.4). 
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These findings highlight that as the disease progressed, discrete syndromes were no longer 
discernible. Indeed, the heterogeneity of the neurological manifestations in the m.13094T>C 
mutation appears similar to that observed in other mtDNA encoded complex I gene 
mutations.  
The most common T2/FLAIR signal abnormalities on cranial MRI were localized to 
the brainstem (71%), thalamus (71%), cerebral cortex (35%) and cervical cord (31%) and 
medial thalamic changes (with restricted diffusion) were identified in seven out of eight 
patients presenting with refractory epilepsy. Such findings suggest prolonged seizure activity 
(focal status epilepticus) as the underlying pathophysiological mechanism of the radiological 
(and clinical) changes observed.19 MRI abnormalities in cortical and/or subcortical areas, 
cerebellar hemispheres (crossed cerebellar diaschisis, which refers to cerebellar 
hypometabolism is ascribed to functional disconnection of the contralateral hemisphere from 
the cerebral cortex)20 corpus callosum, thalami and basal ganglia have been increasingly 
reported in cases of isolated seizures, seizure clusters, and status epilepticus.19 Moreover, the 
development of cognitive dysfunction in these patients may be explained by the observed 
involvement of the cerebello-thalamo-cortical pathway (white matter tracts connecting the 
cerebellar cortex to the contralateral various cerebral cortices, passing through the superior 
cerebellar peduncle, red nuclear and the thalamus).21 T2/FLAIR signal abnormality involving 
the brainstem extending into the upper cervical cord was identified in four patients. 
Interestingly, Patient 5 had quite extensive T2/FLAIR signal changes spanning from C2 to 
C6, mimicking a demyelinating disorder but CSF restricted oligoclonal bands and anti-
aquaporin 4 antibodies both tested negative. Whilst MR imaging findings are consistent with 
previously documented changes in other complex I deficient patients, it is striking that only 
two patients with the m.13094T>C mutation had evidence of striatal lesions14 compared to 
90% of complex I cases reported by Lebre and colleagues.22 These findings are corroborated 
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by relative preservation of the striatum and the presence of devastating destruction of the 
thalami and brainstem with marked capillary proliferation on autopsy examination. Whilst 
symmetrical signal abnormalities in basal ganglia are the most common radiological finding 
in patients affected by LS, lesions may merely be confined to the brainstem23,24, as was 
observed in all our cases. This again serves as a reminder that the diagnosis of LS (including 
due to MT-ND5 mutations) should be considered even in the absence of symmetrical basal 
ganglia lesions. 
 The radiological appearances of patients with LS harboring the m.13094T>C 
mutation bear similarities to mitochondrial diseases caused by autosomal recessive tRNA 
synthetase mutations, such as leukoencephalopathy with thalamus and brainstem involvement 
and high lactate (LTBL) caused by EARS2 mutations and leukoencephalopathy with 
brainstem and spinal cord involvement and lactate elevation (LBSL) caused by DARS2 
mutations.25 In two of our cases, the radiological diagnosis was thought to be a space- 
occupying lesion at presentation. However, the ‘relapsing-remitting’ course of neurological 
deficits associated with m.13094T>C-related mitochondrial disease, coupled with the 
evolution of signal abnormalities on interval brain imaging and demonstration of abnormal 
signals in different regions of structurally normal brain on T1 images (but abnormal cerebral 
metabolism on MR spectroscopy), should aid clinicians to discern between the two 
conditions.  
The clinical features of these patients may also overlap at various stages of the disease 
with other more common forms of mitochondrial disease, such as LHON, OPA1, and POLG-
related disease, and may mimic other forms of hereditary ataxia. In addition, m.13094T>C-
related mitochondrial disease may mimic inflammatory CNS disorders such as acute 
disseminated encephalomyelitis (ADEM), multiple sclerosis (MS) and neuromyelitis optica 
(Patients 5, 6 and 7). Indeed, the link of an MS-like illness and common LHON mutations is 
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well recognized in Harding disease, where imaging appearances are frequently 
indistinguishable from MS.26 More recently, the coincidental occurrence of an MS-like 
disorder and OPA1 mutations in three unrelated patients has also been reported.27 
We observed that the histochemical changes such as ragged red  and COX deficient 
fibres, and biochemical analysis of mitochondrial respiratory chain activity in muscle tissue, 
was normal in 60% of the cases presented here, similar to other point mutations in MT-
ND5.8,10,11 In addition, the quadruple immunohistochemistry technique could not detect the 
reduction of complex I subunit in muscle tissue in one of our patients,28 in accordance with 
the findings of preferential CNS manifestations in association with this mutation. 
Interestingly, the threshold level of mutant mitochondrial load necessary to cause symptoms 
in these cases appears to be much lower than in mitochondrial tRNA gene-related disorders 
associated with severe clinical phenotypes. However, our findings corroborate previous 
findings in transmitochondrial cybrid models of the m.13094T>C mutation.14 Furthermore, 
severe clinical phenotypes associated with a relatively low mutant load have also been 
observed in other common point mutations in the MT-ND5 gene, including the m.13513G>A 
mutation, where a mutant load of less than 50% in muscle has been reported in association 
with LS8 and MELAS.9 Preliminary pedigree analysis did not initially prove informative; 
however, extensive segregation testing confirmed this to be a maternally inherited genetic 
disorder. In addition, our findings highlight the importance of recognizing that mtDNA 
disease can only be definitively excluded by performing whole mitochondrial genome 
sequencing in post-mitotic tissues, such as muscle. In the case of predictive testing, we would 
advocate screening for the m.13094T>C mutation in muscle and/or urine to minimize the 
chance of false-negative results. The variable tissue segregation was further evident and 
exemplified by the variable mutation load in multiple tissues at autopsy (Patients 1.2 and 13). 
Intriguingly, the variable phenotypic threshold effect associated with the m.13094T>C 
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mutation would support the assertion that MT-ND5 synthesis is a rate limiting step for 
complex I activity29, given the relatively low mutant load resulting in severe phenotypic 
expression.7 Although we do not have serial measurements of the m.13094T>C mutant load 
in blood for individual patients, our data suggest that mutant mtDNA heteroplasmy level may 
decline with age, and we would hypothesize that there is a negative selection of this mutant 
mtDNA in bone marrow over time, as demonstrated in other commoner mtDNA mutations 
such as m.3243A>G and m.13513G>A. However, we concede there is a possibility of 
ascertainment bias in the older individuals with lower mutant heteroplasmy levels.  
Patients 1.2 and 8 had MELAS/LS overlapping syndrome whilst Patient 13 had LS 
only. Patient 1.2 predominantly manifested with a childhood onset CNS disorder, with no 
evidence of myopathy (on clinical examination), cardiomyopathy, renal impairment or 
hepatic disease. However, in Patient 1.2, the mutant heteroplasmy levels were much higher in 
skeletal muscle (88%), heart (75%), kidney (83%) and liver (83%) compared to CNS tissues 
(~67%. Only patient 8 manifested with stroke-like episodes and subsequently a brainstem 
crisis in her 30s, yet the mutant mtDNA heteroplasmy levels in CNS tissues (~52%) were 
lower than in Patient 1.2. The tissue specificity of phenotypic expression in this mutation is 
intriguing, and the possible underlying reasons require further elucidation yet support the 
observation that mutant heteroplasmy level alone does not fully explain clinical 
manifestation.30   
In summary, the m.13094T>C mutation exhibits highly variable neurological 
manifestations and is frequently associated with high disease burden and early mortality. 
Cortico-thalamic-cerebellar involvement appears to be a frequent finding in these patients 
compared to other rare mtDNA mutations, and may serve as a radiological biomarker of 
m.13094T>C – related mitochondrial disease. Moreover, our findings would suggest 
m.13094T>C–related mitochondrial disease is perhaps not as rare as originally thought. We 
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would suggest that consideration should be given to screening the whole mtDNA genome in 
clinically relevant tissues, prior to proceeding to whole exome sequencing, in those who have 
tested negative for the commonly recognized disease causing genes and mtDNA point 
mutations. Once again, the observed clinical heterogeneity, often apparent lack of maternal 
inheritance, normal histological and biochemical muscle biopsy findings, and variability in 
tissue segregation in these cases, highlights the diagnostic challenges of mitochondrial 
disease caused by rare mtDNA variants.  We suggest, these findings support a better 
understanding of m.13094T>C –related syndromes and their inherent clinical trajectory and 
as such will serve to aid a more timely diagnosis, inform accurate genetic counseling, and 
facilitate tailored therapeutic interventions. 
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Research in context 
The m.13094T>C mutation in MT-ND5 was considered a rare cause of mitochondrial disease 
that had been previously reported in association with Leigh Syndrome only. This study 
revealed that the m.13094T>C mutation is associated with severe, variable neurological 
features, with a more extensive phenotypic spectrum of disease, frequently manifesting at 
lower mutant heteroplasmy levels compared to many other primary mitochondrial DNA 
mutations. The work described here proposes that an unexplained central nervous system 
disorder should raise clinical suspicion of a mitochondrial disorder, and full mtDNA genome 
sequencing should be considered even with normal muscle biopsy findings. 
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Figure Legend 
Figure 1. Cranial and spine MRI. Axial T2-weighted view of Patient 1·2 showed 
hyperintensities involving the cortical and subcortical areas of left frontal lobe when she 
presented with the first stroke-like episode (A); the cranial MRI performed during the 
subsequent stroke-like episode showed hyperintensities involving the left parietal lobe and 
right cerebellar cortex, suggestive of cross cerebellar diaschisis (B) and extensive signal 
abnormalities in the brainstem (C, coronal view). Axial T2-weighted view of Patient 2 
showed an isolated, left thalamic lesion (D). Axial T2 view (E) showed a discrete signal 
abnormality in the right cerebellum, and asymmetrical hyperintensities in the medulla in 
Patient 4.  The sagittal T2 view (F) showed an anterior, long hyperintensity in the cervical 
cord spanning C2-6 levels in Patient 5, corroborated with the signal abnormalities shown in 
the axial view (G).   
Figure 2. Heteroplasmy levels of the m.13094T>C mutation. (A) A negative correlation 
between age and blood mutant heteroplasmy level. (B) Distribution of mutant heteroplasmy 
levels for individual patient. The numbering of X-axis corresponds to the patient number of 
Table 1.  
Figure 3. Neuropathological features of Patient 1.2 and 8. Patient 1.2: The posterior 
cerebellar cortex is affected by multiple necrotic lesions (demarcated by *) demonstrating 
atrophy of the molecular layer, Purkinje cell dropout and granule cell loss (A; LFB H&E) and 
total necrosis of the cortex and underlying white matter (B; LFB H&E). The basis pontis 
demonstrates a devastating lesion with total neuronal cell loss (C; red dashed line; LFB 
H&E). Scale bar = 100 microns. 
Patient 8: The lower midbrain shows devastated inferior colliculus with prominent capillary 
proliferation (arrows), microvacuolation and severe neuronal cell loss (D; H&E). The 
thalamus (E; LFB H&E) and subthalamic nucleus (F; H&E) are devastated featuring 
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prominent capillary proliferation (arrows), microvacuolation, severe neuronal cell loss and 
morphologically normal neurons scattered throughout (arrowhead). The occipital lobes reveal 
microvacuolation and laminar necrosis of the cortical layers within Broadmann area 17 (G; 
LFB H&E) with the underlying white matter demonstrating myelin pallor relative to 
otherwise preserved myelin. The cortex features microvacuolation, severe neuronal cell loss 
and capillary proliferation. Surviving neurons within the inferior colliculus lack complex I 
subunit expression (H; NDUFB8 IHC, arrows) while mitochondrial mass is high (I; SDHA 
IHC, arrows).  
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Table Legend  
Table 1. Syndromic classification and clinical features of individuals with the 
m.13094T>C mutation (n=24).  *=deceased, AO= age of onset, AL= age of last follow up 
or death, B/L INO= bilateral inter-nuclear ophthalmoplegia, Dev delay= developmental delay 
(including motor and speech), F= female, HCM= hypertrophic cardiomyopathy, HTN= 
hypertension, LA= lactic acidosis, LS= Leigh syndrome, LVH= left ventricular hypertrophy, 
M= male, MELAS= mitochondrial encephalomyopathy, lactic acidosis and stroke-like 
episodes, mths= months, n.d.= not done, NIV= non invasive ventilation, n.k.= not known, 
ON= optic neuropathy, PEG= percutaneous endoscopic gastrostomy, PFO= patent foramen 
ovale, PN= peripheral neuropathy, Psy= neuropsychiatric symptoms such as severe 
depression, anxiety or personality change, RF= respiratory failure, SCA= spinocerebellar 
ataxia, SLE= stroke-like episodes, yrs= years.  
Table 2. Cranial MRI changes associated with the m.13094T>C mutation (n=17). All 
cortical lesions (including cerebellar cortex) exhibited restricted diffusion. B/L= bilateral, 
CR= corona radiata, F= frontal lobe, H= hippocampus, L= left, n.k.= not known, O= occipital 
lobe, P= parietal lobe, R= right, T= temporal lobe, U/L= unilateral, Δ= Patient 2·2 had a 
history of clinically and radiologically defined lacunar stroke (internal capsule and corona 
radiate), *= the extent of cervical lesion had not been clearly defined  
Table 3. The m.13094T>C heteroplasmy levels in different postmortem tissues. 
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Table Legend  
Table 1. Syndromic classification and clinical features of individuals with the 
m.13094T>C mutation (n=24).  *=deceased, AO= age of onset, AL= age of last follow up 
or death, Ap= apnoea, At= ataxia, B= blood, B/L INO= bilateral inter-nuclear 
ophthalmoplegia, Brady= bradycardia, Cog= cognitive impairment, Dev delay= 
developmental delay (including motor and speech), F= female, Fib= fibrolast, HCM= 
hypertrophic cardiomyopathy, HTN= hypertension, LA= lactic acidosis, LS= Leigh 
syndrome, LVH= left ventricular hypertrophy, M= male, MELAS= mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes, mths= months, Mu= muscle, 
n.d.= not done, NIV= non-invasive ventilation, n.k.= not known, ON= optic neuropathy, 
PEG= percutaneous endoscopic gastrostomy, PFO= patent foramen ovale, PN= peripheral 
neuropathy, Psy= neuropsychiatric symptoms such as severe depression, anxiety or 
personality change, Pt= ptosis, RF= respiratory failure, SCA= spinocerebellar ataxia, SLE= 
stroke-like episodes, Str= strabismus, Sz= seizures, trachy= tracheostomy, U= urine, yrs= 
years.  
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Table 2. Cranial MRI changes associated with the m.13094T>C mutation (n=17). All cortical 
lesions (including cerebellar cortex) exhibited restricted diffusion. B/L= bilateral, CR= corona radiata, 
F= frontal lobe, H= hippocampus, L= left, n.k.= not known, O= occipital lobe, P= parietal lobe, R= 
right, T= temporal lobe, U/L= unilateral, Δ= Patient 2·2 had a history of clinically and radiologically 
defined lacunar stroke (internal capsule and corona radiate), *= the extent of cervical lesion had not 
been clearly defined  
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Dentate 
nuclei 
Cort
ex 
Atrop
hy 
Midbr
ain 
Po
ns 
Med
ulla cord 
1 36 P, T (R) 
- U/L 
(R) - - + - - - - 
Yes 
1.1 8 mths - 
- 
B/L - - - + + + C1-2 
n.k. 
1.2 13; 14 P, O, H (L) 
- 
B/L + + + + + + C1 
Yes 
2 26; 30 O (R) 
- 
U/L (L) - - - - - - - 
Yes 
2.2 66 Δ 
- 
- - - - - - - - 
No 
2.4 31 - 
- 
B/L + + + + + + - 
n.k. 
3 3 mths - 
- 
B/L - - - + + + +* 
n.k. 
4 6 - 
- 
- + - - + - + - 
n.k. 
5 13; 14 
F (B/L), P 
(B/L) 
- 
B/L - + + + + - C2-6 
Yes 
6 2.25 - 
- 
B/L - - - + + + - 
No 
7 7 - 
- 
- - - - - - - - 
n.k. 
8 33 O (R) 
- 
B/L - - - + - - - 
Yes 
9 34 
O (B/L), 
P,T,F(L)  
 
- - - - - - - - n.k. 
 
Yes 
10 24 - 
- 
- - - - + + + - 
n.k. 
11 22, 23 - 
 
+ 
U/L - - + + + + 
+ 
(upper
)* 
 
Yes 
12 
1 yr 4 
mths - 
- 
B/L - - - + + + n.k. 
Yes 
13 10 - 
+  
B/L - - - + + - - 
No 
 Total 6/17 
 
2/17 12/17 3/17 3/17 5/17 12/17 
10/
17 9/17 5/15 
 
8/11 
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Table 3. The m.13094T>C heteroplasmy levels in different post-mortem tissues. 
 Patient 1.2 Patient 8 Patient 13 
Syndrome MELAS/LS MELAS/LS LS 
Age of death 14 35 14 
Post-mortem tissues    
Heart 75% - 64% 
Adrenal Gland 96% - - 
Liver 83% - 23% 
Kidney 83% - 56% 
Bladder 90% -  
Skeletal muscle 88% - 52% 
Intestine 69% - 24% 
Lung - - 28% 
Frontal lobe 69% 47% - 
Hippocampus 67% 52% - 
Cerebellum 64% 58% - 
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Highlights 
 The m.13094T>C mutation in MT-ND5 is associated with severe, variable 
neurological manifestations. 
 Whole mtDNA genome sequencing should be considered in patients with 
undiagnosed complex neurological disorders.  
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